doi: 10.1007/BF00306736.
A new triphenylethylene compound, Fc-1157a. I. Hormonal effects
- PMID: 2941176
- DOI: 10.1007/BF00306736
Item in Clipboard
A new triphenylethylene compound, Fc-1157a. I. Hormonal effects
Cancer Chemother Pharmacol.
1986.
Abstract
The basic pharmacological and biochemical properties of a new antiestrogen, Fc-1157a, are described. Fc-1157a is bound specifically and with high affinity to estrogen receptors. The binding is competitive with estradiol. Fc-1157a treatment induces translocation of estrogen receptors from cytoplasm to nucleus. The turnover rate of nuclear estrogen receptors is markedly lower than with estradiol, but is more rapid than after tamoxifen. Fc-1157a is an almost pure antiestrogen in rat uterus, but has intrinsic estrogenic activity in mouse uterus. In animal experiments Fc-1157a has shown antitumor properties, which are described in the companion paper.
Similar articles
-
A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.Cancer Chemother Pharmacol. 1986;17(2):109-13. doi: 10.1007/BF00306737. Cancer Chemother Pharmacol. 1986. PMID: 2941177
-
Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen.Endocrinology. 1980 Dec;107(6):2011-20. doi: 10.1210/endo-107-6-2011. Endocrinology. 1980. PMID: 7191796
-
Tamoxifen decreases the estradiol induced progesterone receptors by interfering with nuclear estrogen receptor accumulation.J Steroid Biochem. 1989 Jul;33(1):133-9. doi: 10.1016/0022-4731(89)90368-3. J Steroid Biochem. 1989. PMID: 2761261
-
Review of the pharmacological properties of toremifene.J Steroid Biochem. 1990 Jun 22;36(3):191-5. doi: 10.1016/0022-4731(90)90003-b. J Steroid Biochem. 1990. PMID: 2142231 Review.
-
The agonistic and antagonistic properties of the high affinity antiestrogen--H1285.Pharmacol Ther. 1983;21(2):247-64. doi: 10.1016/0163-7258(83)90075-x. Pharmacol Ther. 1983. PMID: 6312469 Review. No abstract available.
Cited by
-
Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.Drugs. 1997 Jul;54(1):141-60. doi: 10.2165/00003495-199754010-00014. Drugs. 1997. PMID: 9211086 Review.
-
Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice.Cancer Chemother Pharmacol. 1993;32(5):353-8. doi: 10.1007/BF00735918. Cancer Chemother Pharmacol. 1993. PMID: 8339385
-
The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene.Cancer Immunol Immunother. 1990;31(6):381-6. doi: 10.1007/BF01741410. Cancer Immunol Immunother. 1990. PMID: 2143689 Free PMC article.
-
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.Br J Cancer. 1997;76(2):270-7. doi: 10.1038/bjc.1997.375. Br J Cancer. 1997. PMID: 9231932 Free PMC article. Clinical Trial.
-
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).Breast Cancer Res Treat. 1995;36(1):35-40. doi: 10.1007/BF00690182. Breast Cancer Res Treat. 1995. PMID: 7579504 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources